neuroblastoma (Cancer)
Information
- Disease name
- neuroblastoma
- Disease ID
- DOID:769
- Description
- "An autonomic nervous system neoplasm that derives_from immature nerve cells." [url:http\://www.cancer.gov/cancertopics/types/neuroblastoma]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| ARID1B | 6 | 156,777,378 | 157,210,779 | 72 |
| ARID1A | 1 | 26,696,015 | 26,782,104 | 56 |
| ALK | 2 | 29,192,774 | 29,921,586 | 38 |
| ATRX | X | 77,504,880 | 77,786,216 | 36 |
| PHOX2B | 4 | 41,744,082 | 41,748,725 | 16 |
| HRAS | 11 | 532,243 | 535,550 | 8 |
| PTPN11 | 12 | 112,419,112 | 112,504,764 | 8 |
| KRAS | 12 | 25,205,246 | 25,250,929 | 8 |
| NRAS | 1 | 114,704,469 | 114,716,771 | 8 |
| MYCN | 2 | 15,940,550 | 15,947,004 | 2 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00085930 | Active, not recruiting | Phase 1 | Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients | April 2003 | December 2024 |
| NCT03126916 | Active, not recruiting | Phase 3 | Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | May 14, 2018 | September 30, 2026 |
| NCT02245997 | Active, not recruiting | N/A | Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma | September 2014 | September 2024 |
| NCT02176967 | Active, not recruiting | Phase 3 | Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma | August 8, 2014 | September 30, 2026 |
| NCT02076906 | Active, not recruiting | Phase 1 | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors | April 2014 | November 24, 2024 |
| NCT02030964 | Active, not recruiting | Phase 1 | N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan | January 16, 2014 | December 30, 2024 |
| NCT00703222 | Active, not recruiting | Phase 1/Phase 2 | A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells | June 2008 | May 2024 |
| NCT03709680 | Active, not recruiting | Phase 1/Phase 2 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | May 24, 2019 | February 25, 2025 |
| NCT02308527 | Active, not recruiting | Phase 2 | Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children | July 2013 | February 2026 |
| NCT02307630 | Active, not recruiting | N/A | PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study | November 2014 | November 2024 |
| NCT03332667 | Active, not recruiting | Phase 1 | MIBG With Dinutuximab +/- Vorinostat | September 12, 2018 | June 2024 |
| NCT02298348 | Active, not recruiting | Phase 1 | Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma | October 8, 2015 | December 2024 |
| NCT04106219 | Active, not recruiting | Phase 1 | A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma | June 11, 2020 | August 25, 2024 |
| NCT04483778 | Active, not recruiting | Phase 1 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | July 13, 2020 | December 2040 |
| NCT03107988 | Active, not recruiting | Phase 1 | NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) | September 5, 2017 | December 2025 |
| NCT02909777 | Active, not recruiting | Phase 1 | Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma | October 2016 | July 2024 |
| NCT02868268 | Active, not recruiting | Neuroblastoma Precision Trial | August 22, 2016 | December 2024 | |
| NCT02650648 | Active, not recruiting | Phase 1 | Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma | January 2016 | January 2025 |
| NCT03033303 | Active, not recruiting | Phase 2 | A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma | January 23, 2017 | June 2024 |
| NCT05302921 | Active, not recruiting | Phase 2 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | February 18, 2022 | July 1, 2025 |
| NCT01953900 | Active, not recruiting | Phase 1 | iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma | April 2014 | October 31, 2034 |
| NCT01868269 | Active, not recruiting | Phase 3 | Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) | April 18, 2013 | April 2031 |
| NCT01857934 | Active, not recruiting | Phase 2 | Therapy for Children With Advanced Stage Neuroblastoma | July 5, 2013 | December 2024 |
| NCT03478462 | Active, not recruiting | Phase 1 | Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | April 30, 2019 | December 2024 |
| NCT01822652 | Active, not recruiting | Phase 1 | 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN | August 2013 | October 2030 |
| NCT01757626 | Active, not recruiting | Phase 1/Phase 2 | Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma | December 2012 | December 2025 |
| NCT04724369 | Active, not recruiting | Phase 3 | Open-Label Study of 18F-mFBG for Imaging Neuroblastoma | November 18, 2021 | May 1, 2024 |
| NCT04239040 | Active, not recruiting | Phase 1 | GVAX Plus Checkpoint Blockade in Neuroblastoma | January 29, 2020 | January 1, 2027 |
| NCT02573896 | Active, not recruiting | Phase 1 | Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells | January 14, 2019 | September 2024 |
| NCT04029688 | Active, not recruiting | Phase 1/Phase 2 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | January 27, 2020 | December 30, 2025 |
| NCT02311621 | Active, not recruiting | Phase 1 | Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 | November 25, 2014 | November 2038 |
| NCT01192555 | Active, not recruiting | Phase 1/Phase 2 | Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma | September 2010 | September 2026 |
| NCT04385277 | Active, not recruiting | Phase 2 | Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) | December 31, 2020 | September 26, 2024 |
| NCT00996710 | Active, not recruiting | Genomic Structural Variation in Cancer Susceptibility | October 2009 | October 2024 | |
| NCT00911560 | Active, not recruiting | Phase 1/Phase 2 | Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma | May 27, 2009 | May 2025 |
| NCT00730444 | Approved for marketing | Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma | |||
| NCT03581240 | Available | An Intermediate Expanded Use Trial of DFMO | |||
| NCT03015844 | Available | A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma | |||
| NCT01590680 | Available | Expanded Access Protocol Using 131I-MIBG | |||
| NCT01370330 | Available | 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol | |||
| NCT01163383 | Available | 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol | |||
| NCT00006480 | Completed | Phase 1 | Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma | May 2000 | March 2005 |
| NCT00007813 | Completed | Phase 1 | Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors | May 31, 1997 | February 1, 2005 |
| NCT00010283 | Completed | Phase 1/Phase 2 | Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon | July 2000 | July 2002 |
| NCT00017225 | Completed | Phase 2 | Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma | May 1997 | February 2002 |
| NCT00017368 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma | April 2001 | January 2012 |
| NCT00020150 | Completed | Phase 1 | Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors | June 2000 | |
| NCT00020527 | Completed | N/A | Caspofungin Acetate in Treating Children With Fever and Neutropenia | March 2001 | June 2003 |
| NCT00024258 | Completed | Phase 2 | Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors | March 2001 | May 2009 |
| NCT00025428 | Completed | Phase 3 | Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma | December 2000 | November 2013 |
| NCT00025597 | Completed | Phase 2 | Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma. | July 1999 | February 2011 |
| NCT00025610 | Completed | Phase 2 | Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma | July 1999 | March 2009 |
| NCT00025623 | Completed | Phase 2 | Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma | July 1999 | March 2009 |
| NCT00025649 | Completed | Phase 2 | Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma | July 1999 | March 2009 |
| NCT00026780 | Completed | Eligibility Screening for a NCI Pediatric Oncology Branch Research Study | September 24, 2001 | October 7, 2020 | |
| NCT00030108 | Completed | Phase 1 | Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy | November 2001 | April 2010 |
| NCT00036959 | Completed | Phase 1 | ABT-751 in Treating Young Patients With Refractory Solid Tumors | March 2002 | February 2010 |
| NCT00037011 | Completed | Phase 1 | Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma | November 2001 | |
| NCT00040872 | Completed | Phase 2 | Multiple Therapies in Treating Patients With Advanced Neuroblastoma | June 2000 | January 2007 |
| NCT00040911 | Completed | N/A | Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma | April 2005 | January 2011 |
| NCT00048386 | Completed | Phase 1 | Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy | November 1999 | October 2009 |
| NCT00049023 | Completed | Phase 1 | Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors | January 2002 | August 2011 |
| NCT00053118 | Completed | Phase 1 | Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer | March 2002 | July 2004 |
| NCT00062855 | Completed | Phase 1 | Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma | November 1997 | March 2006 |
| NCT00064311 | Completed | Phase 1/Phase 2 | Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation | June 2003 | September 2004 |
| NCT00066599 | Completed | Phase 2 | Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy | June 2003 | June 2004 |
| NCT00070200 | Completed | Phase 1 | Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma | March 2004 | December 2013 |
| NCT00072358 | Completed | Phase 2 | Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma | July 2003 | January 15, 2021 |
| NCT00080873 | Completed | N/A | Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation | April 2004 | January 2011 |
| NCT00082654 | Completed | N/A | Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients | March 2002 | October 2004 |
| NCT00082758 | Completed | Phase 2 | hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma | August 2005 | May 2012 |
| NCT00083135 | Completed | Phase 1 | N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation | March 2004 | |
| NCT00084422 | Completed | Phase 1 | N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma | August 2003 | February 2011 |
| NCT00089258 | Completed | Phase 2 | Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment | July 2004 | |
| NCT00093353 | Completed | Phase 1 | N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma | May 2004 | |
| NCT00098865 | Completed | Phase 2 | Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma | September 2002 | June 2010 |
| NCT00109993 | Completed | Phase 2 | Campath-1H + FK506 and Methylprednisolone for GVHD | January 2005 | May 2007 |
| NCT00112645 | Completed | Phase 1 | Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors | April 2005 | February 2011 |
| NCT00118326 | Completed | Phase 1/Phase 2 | Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease | August 2003 | May 2007 |
| NCT00126412 | Completed | Phase 3 | Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma | August 2, 2005 | September 27, 2006 |
| NCT00132158 | Completed | Phase 1 | ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors | September 2005 | October 2011 |
| NCT00135135 | Completed | Phase 2 | Therapy for Children With Neuroblastoma | August 2005 | June 2007 |
| NCT00152126 | Completed | N/A | Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas | August 2003 | February 2009 |
| NCT00165139 | Completed | Phase 2 | Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas | January 1996 | February 2009 |
| NCT00186849 | Completed | Phase 2 | Therapy for Children With Advanced Stage High Risk Neuroblastoma | October 1997 | April 2001 |
| NCT00186862 | Completed | Phase 1 | Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma | August 1998 | October 2007 |
| NCT00187109 | Completed | Phase 1/Phase 2 | Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy | June 2000 | February 2007 |
| NCT00206388 | Completed | Phase 1 | Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement | April 2005 | May 2013 |
| NCT00253435 | Completed | Phase 2 | N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma | September 2005 | December 2013 |
| NCT00276679 | Completed | Phase 2 | Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma | April 2003 | November 2006 |
| NCT00293319 | Completed | Phase 2 | 131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma | April 2005 | March 2006 |
| NCT00001335 | Completed | Phase 2 | New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma | April 1993 | January 2002 |
| NCT00295919 | Completed | Phase 1 | N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma | December 2005 | May 2015 |
| NCT00303940 | Completed | Phase 1 | Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors | December 2005 | February 2010 |
| NCT00311584 | Completed | Phase 2 | Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma | April 2006 | December 2013 |
| NCT00336531 | Completed | Phase 4 | Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation | April 2006 | October 2008 |
| NCT00357500 | Completed | Phase 2 | Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer | January 2005 | December 2013 |
| NCT00365755 | Completed | Phase 3 | Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma | March 2008 | |
| NCT00405327 | Completed | Phase 2 | A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation | June 2006 | June 2010 |
| NCT00407433 | Completed | Phase 2 | Clinical Studies of Gemcitabine-Oxaliplatin | ||
| NCT00410657 | Completed | Phase 2 | Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant | July 2006 | |
| NCT00436657 | Completed | Phase 1 | Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer | February 2007 | April 2011 |
| NCT00445965 | Completed | Phase 2 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | January 2006 | February 1, 2023 |
| NCT00450307 | Completed | Phase 1 | Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma | June 2005 | April 2013 |
| NCT00450827 | Completed | Phase 1 | Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma | August 2006 | August 2015 |
| NCT00471679 | Completed | Phase 1 | Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk Neuroblastoma | April 2007 | February 2010 |
| NCT00486564 | Completed | Phase 1 | Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma | November 2006 | June 2009 |
| NCT00492167 | Completed | Phase 1 | Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma | September 9, 2005 | March 4, 2022 |
| NCT00499616 | Completed | Phase 3 | Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma | October 8, 2007 | June 30, 2021 |
| NCT00503724 | Completed | Phase 1 | Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors | June 2007 | May 2010 |
| NCT00509353 | Completed | Phase 1 | N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma | January 2007 | May 2012 |
| NCT00578864 | Completed | Phase 2 | Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma | March 2007 | March 2015 |
| NCT00590096 | Completed | I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma | January 1991 | December 2008 | |
| NCT00601003 | Completed | Phase 2 | Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma | January 14, 2008 | October 28, 2022 |
| NCT00608452 | Completed | Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers | July 1995 | November 2009 | |
| NCT00644696 | Completed | Phase 1 | Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma | April 2008 | July 2012 |
| NCT00646230 | Completed | Phase 1 | N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma | December 2006 | March 2012 |
| NCT00659984 | Completed | Phase 2 | N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma | June 2008 | November 2010 |
| NCT00716976 | Completed | Phase 3 | Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy | June 23, 2008 | June 30, 2021 |
| NCT00726934 | Completed | N/A | The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients | September 2007 | January 2017 |
| NCT00743496 | Completed | Phase 1 | A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma | October 8, 2008 | April 18, 2014 |
| NCT00754286 | Completed | N/A | A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer | July 2008 | July 2011 |
| NCT00782145 | Completed | Phase 3 | A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families | June 2008 | June 2011 |
| NCT00293384 | Completed | N/A | Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant | October 2004 | February 2012 |
| NCT00001509 | Completed | Phase 2 | A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor | July 1996 | May 2000 |
| NCT00001565 | Completed | Phase 1 | Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy | December 1996 | October 2000 |
| NCT00002458 | Completed | Phase 2 | Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission | November 1987 | September 2001 |
| NCT00002485 | Completed | Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer | February 1992 | September 2005 | |
| NCT00002515 | Completed | Phase 2 | Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer | October 1992 | April 2005 |
| NCT00002543 | Completed | Phase 1 | Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors | February 1995 | October 2004 |
| NCT00002560 | Completed | Phase 2 | Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma | February 1994 | April 2005 |
| NCT00002634 | Completed | Phase 2 | Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma | February 1995 | September 2004 |
| NCT00002730 | Completed | Phase 1 | Chemotherapy in Treating Children With Neuroblastoma | June 1996 | |
| NCT00002740 | Completed | Phase 1 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma | May 1996 | September 2005 |
| NCT00002748 | Completed | Phase 1 | Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma | December 1991 | August 2007 |
| NCT00002802 | Completed | Phase 3 | Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma | July 1990 | September 2003 |
| NCT00002803 | Completed | Phase 2 | Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma | July 1995 | February 2002 |
| NCT00002825 | Completed | Phase 2 | Docetaxel in Treating Children With Recurrent Solid Tumors | January 1997 | |
| NCT00003022 | Completed | Phase 1 | Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer | April 1997 | January 2005 |
| NCT00003023 | Completed | Phase 1 | Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer | March 1997 | |
| NCT00003093 | Completed | Phase 3 | Combination Chemotherapy in Treating Children With Neuroblastoma | March 1988 | January 2011 |
| NCT00003107 | Completed | Phase 1 | Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors | October 1997 | |
| NCT00003119 | Completed | Phase 3 | Surgery in Treating Children With Neuroblastoma | March 1998 | March 2006 |
| NCT00003141 | Completed | Phase 1 | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors | March 1998 | October 2011 |
| NCT00003191 | Completed | Phase 1 | Fenretinide in Treating Children With Solid Tumors | March 1998 | |
| NCT00003203 | Completed | Phase 2 | Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors | March 1998 | March 2012 |
| NCT00003234 | Completed | Phase 2 | Vinorelbine in Treating Children With Recurrent or Refractory Cancers | May 1998 | March 2007 |
| NCT00003408 | Completed | Phase 2 | Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer | April 1998 | March 2000 |
| NCT00003425 | Completed | Phase 1/Phase 2 | Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect | December 1997 | |
| NCT00003461 | Completed | Phase 1/Phase 2 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors | February 1998 | February 2005 |
| NCT00003484 | Completed | Phase 1 | Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors | September 1997 | March 2010 |
| NCT00003661 | Completed | Phase 2 | Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | June 1998 | March 2006 |
| NCT00003737 | Completed | Phase 2 | Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma | January 1999 | September 2006 |
| NCT00003750 | Completed | Phase 1 | Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors | October 2001 | September 2005 |
| NCT00003846 | Completed | Phase 2 | Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors | July 1999 | March 2007 |
| NCT00003887 | Completed | Phase 2 | Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation | August 1998 | February 2003 |
| NCT00004110 | Completed | Phase 2 | Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma | August 1999 | |
| NCT00004157 | Completed | Phase 2 | Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors | August 2000 | April 2002 |
| NCT00004188 | Completed | Phase 3 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma | February 2001 | |
| NCT00005835 | Completed | Phase 1 | N99-02: Melphalan and Buthionine Sulfoximine | August 2001 | April 2016 |
| NCT00005952 | Completed | Phase 1/Phase 2 | Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors | August 2000 | November 2005 |
| NCT00005955 | Completed | Phase 2 | Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors | August 2000 | September 2002 |
| NCT00005978 | Completed | Phase 1 | N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma | May 2000 | |
| NCT00006102 | Completed | Phase 2 | Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma | July 2000 | |
| NCT00793351 | Completed | Phase 2 | Reduced Intensity Stem Cell Transplantation in Children With Relapsed Neuroblastoma After Autologous Transplantation | September 2008 | November 2015 |
| NCT00793845 | Completed | Phase 2 | Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma | August 2008 | January 2018 |
| NCT00867568 | Completed | Phase 1 | TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma | March 2009 | February 2016 |
| NCT00877110 | Completed | Phase 1 | Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma | April 2, 2009 | January 7, 2019 |
| NCT00885326 | Completed | Phase 1 | N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma | December 2009 | December 2019 |
| NCT00900406 | Completed | Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant | January 2007 | March 2010 | |
| NCT00907920 | Completed | Studying Tumor Samples From Young Patients With Neuroblastoma | December 2008 | December 2008 | |
| NCT00918320 | Completed | Phase 2 | Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours | June 2009 | August 2015 |
| NCT00923351 | Completed | Phase 1/Phase 2 | Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma | June 2, 2007 | May 15, 2018 |
| NCT00923650 | Completed | Informed Consent in Pediatric Cancer Trials | December 9, 2008 | February 2, 2010 | |
| NCT00931931 | Completed | Phase 1 | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | March 2010 | March 19, 2018 |
| NCT00960739 | Completed | Phase 2 | Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma | November 2008 | July 2016 |
| NCT01019850 | Completed | Phase 1 | N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma | March 2010 | February 2015 |
| NCT01048892 | Completed | Phase 1 | Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features | September 2009 | |
| NCT01058798 | Completed | The Role of Glycosyltransferases in the Oncogenesis of Neuroblastoma | January 2008 | April 2009 | |
| NCT01059071 | Completed | Phase 1 | Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide | February 2010 | May 2015 |
| NCT01075360 | Completed | The Role of Aromatic Hydrocarbon Receptor in the Tumorigenesis of Neuroblastoma and Its Relationship With MYCN Expression | August 2008 | April 2009 | |
| NCT01095926 | Completed | Phase 2 | Pharmacokinetic Study of Doxorubicin in Children With Cancer | May 2010 | May 2013 |
| NCT01114555 | Completed | Phase 2 | Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma | April 29, 2010 | November 2, 2018 |
| NCT01119560 | Completed | Genetic Susceptibility Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA]) | February 3, 2009 | December 31, 2018 | |
| NCT01121419 | Completed | The Role of IMP3 Expression in Patients With Neuroblastoma | January 2008 | January 2009 | |
| NCT01125800 | Completed | Phase 1/Phase 2 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | February 2011 | October 2014 |
| NCT01132911 | Completed | Phase 1 | A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas | May 10, 2010 | April 13, 2011 |
| NCT01169376 | Completed | Biomarkers in Young Patients With Neuroblastoma | July 2010 | May 2016 | |
| NCT01169584 | Completed | Phase 1 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients | August 2010 | November 2014 |
| NCT01183416 | Completed | Phase 2 | High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation | August 2010 | October 31, 2018 |
| NCT01183429 | Completed | Phase 2 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma | August 12, 2010 | September 13, 2018 |
| NCT01183897 | Completed | Phase 2 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow | August 12, 2010 | September 25, 2018 |
| NCT01222780 | Completed | Phase 1 | To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer | September 2010 | December 2014 |
| NCT01241162 | Completed | Phase 1 | Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma | August 2010 | October 2016 |
| NCT01288573 | Completed | Phase 1/Phase 2 | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone | March 3, 2014 | May 9, 2017 |
| NCT01313936 | Completed | Phase 1 | High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma | March 2011 | May 2014 |
| NCT01331135 | Completed | Phase 1 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | April 2011 | August 9, 2017 |
| NCT01353300 | Completed | Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Cancer | May 2011 | ||
| NCT01355679 | Completed | N/A | Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma | May 2011 | January 2015 |
| NCT01358604 | Completed | Biomarkers in Samples From Young Patients With Neuroblastoma | May 2011 | April 2016 | |
| NCT01386619 | Completed | Phase 1/Phase 2 | NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) | January 2004 | March 2011 |
| NCT01387724 | Completed | Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma | June 2011 | ||
| NCT01407731 | Completed | Protein Expression in Human Neuroblastoma Tumor Samples | July 2011 | May 2016 | |
| NCT01419834 | Completed | Phase 1 | Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors | August 15, 2011 | August 2, 2023 |
| NCT01445379 | Completed | Phase 1 | Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer | October 1, 2007 | November 13, 2015 |
| NCT01460901 | Completed | Phase 1 | Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma | October 2012 | January 2015 |
| NCT01462396 | Completed | Phase 1 | Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using MHC Mismatched Related Donors | October 2011 | December 2015 |
| NCT01482741 | Completed | Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging | November 2011 | June 2015 | |
| NCT01492673 | Completed | Phase 2 | Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma | December 2011 | October 31, 2018 |
| NCT01493830 | Completed | Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma | December 2011 | ||
| NCT01510600 | Completed | Studying Biomarkers in Samples From Patients With High-Risk Neuroblastoma | January 2012 | May 2016 | |
| NCT01518413 | Completed | Phase 1 | Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors | December 2011 | January 2015 |
| NCT01520233 | Completed | Gene Expression in Predicting Outcome in Samples From Patients With High-Risk Neuroblastoma | January 2012 | May 2016 | |
| NCT01526603 | Completed | N/A | High Dose Chemotherapy and Autologous Transplant for Neuroblastoma | March 28, 2012 | May 30, 2023 |
| NCT01553448 | Completed | Studying Gene Expression in Samples From Younger Patients With Neuroblastoma | March 2012 | ||
| NCT01576692 | Completed | Phase 1 | Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma | April 2012 | October 17, 2018 |
| NCT01589341 | Completed | Studying Chromosomes in Samples From Younger Patients With Neuroblastoma | April 2012 | ||
| NCT01592045 | Completed | Phase 1/Phase 2 | ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma | August 2012 | June 2014 |
| NCT01598454 | Completed | Phase 1 | Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides | February 2011 | June 2015 |
| NCT01601535 | Completed | Phase 1/Phase 2 | Study of MLN8237 in Combination With Irinotecan and Temozolomide | May 2012 | July 25, 2018 |
| NCT01619865 | Completed | Phase 1/Phase 2 | Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors | February 21, 2012 | August 27, 2017 |
| NCT01625351 | Completed | Phase 1 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | August 20, 2012 | February 10, 2020 |
| NCT01638572 | Completed | Exploring the Possibility to Use Glycosyltransferase as a Prognosis Marker of Neuroblastoma | January 2010 | December 2011 | |
| NCT01662804 | Completed | Phase 1 | Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors | August 6, 2012 | May 25, 2021 |
| NCT01704872 | Completed | Phase 1 | ch14.18/CHO Bridging Study | July 2005 | March 2012 |
| NCT01713439 | Completed | Phase 1 | Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL | December 1997 | April 2016 |
| NCT01802138 | Completed | N/A | A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma | February 2013 | October 31, 2018 |
| NCT01802567 | Completed | N/A | Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer | March 4, 2013 | January 17, 2024 |
| NCT01853345 | Completed | iCAT for Recurrent/Refractory/HR Solid Tumors | August 2012 | ||
| NCT01869725 | Completed | Phase 2 | Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT | April 1, 2013 | December 26, 2018 |
| NCT01875601 | Completed | Phase 1 | NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors | June 11, 2013 | September 8, 2015 |
| NCT01962103 | Completed | Phase 1/Phase 2 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | December 4, 2013 | November 6, 2018 |
| NCT02035137 | Completed | Phase 2 | 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat | July 2014 | February 26, 2021 |
| NCT02100891 | Completed | Phase 2 | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors | March 20, 2013 | July 15, 2020 |
| NCT02100930 | Completed | N/A | Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma | March 2014 | March 7, 2019 |
| NCT02107963 | Completed | Phase 1 | A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors | February 28, 2014 | January 31, 2017 |
| NCT02130869 | Completed | Phase 1 | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | October 10, 2014 | December 20, 2017 |
| NCT02159443 | Completed | Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody | July 15, 2014 | April 24, 2020 | |
| NCT02162732 | Completed | N/A | Molecular-Guided Therapy for Childhood Cancer | July 8, 2014 | January 18, 2024 |
| NCT02169609 | Completed | Phase 2 | Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma | November 26, 2014 | December 31, 2018 |
| NCT02390843 | Completed | Phase 1 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors | February 2015 | September 22, 2019 |
| NCT02395666 | Completed | Phase 2 | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | March 5, 2015 | August 24, 2023 |
| NCT02441062 | Completed | Phase 2 | Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors | September 2015 | January 20, 2020 |
| NCT02444884 | Completed | Phase 1 | MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors | September 2008 | December 2011 |
| NCT02765243 | Completed | Phase 1 | Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma | January 1, 2016 | December 30, 2023 |
| NCT02786719 | Completed | N/A | High-Risk Neuroblastoma Chemotherapy Without G-CSF | June 2016 | February 5, 2019 |
| NCT02864563 | Completed | N/A | Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification | October 4, 2008 | July 2023 |
| NCT02924324 | Completed | N/A | Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients | October 2016 | November 2019 |
| NCT02982941 | Completed | Phase 1 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | December 2016 | May 22, 2019 |
| NCT02998983 | Completed | Phase 2 | Racotumomab in Patients With High-risk Neuroblastoma | November 2016 | November 2022 |
| NCT03042416 | Completed | Phase 3 | 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety | June 29, 2017 | June 2, 2021 |
| NCT03042429 | Completed | Phase 3 | Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients | January 1, 2007 | December 31, 2016 |
| NCT03236857 | Completed | Phase 1 | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | November 8, 2017 | April 19, 2023 |
| NCT03273712 | Completed | Phase 2 | Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | September 29, 2017 | May 27, 2020 |
| NCT03291080 | Completed | Phase 1/Phase 2 | Oral Liquid 13-cis-retinoic Acid (13-CRA) | April 17, 2018 | September 12, 2019 |
| NCT03517280 | Completed | Nutritional Status in Neuroblastoma in Sao Paolo, Brazil | July 15, 2018 | May 10, 2023 | |
| NCT03686566 | Completed | Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics] | November 16, 2018 | January 26, 2024 | |
| NCT04474678 | Completed | N/A | Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") | September 7, 2020 | December 31, 2023 |
| NCT05245123 | Completed | Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families | February 21, 2022 | March 31, 2023 | |
| NCT06190574 | Completed | Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid Blastoma | July 30, 2021 | November 30, 2023 | |
| NCT01838187 | No longer available | Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma | |||
| NCT02431715 | No longer available | 18F-FDOPA PET in Neuroendocrine Tumours | |||
| NCT02075177 | No longer available | Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma | |||
| NCT05918432 | Not yet recruiting | Determining Patterns In Study Experiences of Neuroblastoma Patients | July 2024 | July 2026 | |
| NCT06450041 | Not yet recruiting | Phase 2 | NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial | July 2024 | December 2038 |
| NCT06395103 | Not yet recruiting | Phase 1/Phase 2 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | June 4, 2024 | March 31, 2029 |
| NCT05303727 | Not yet recruiting | Phase 2 | Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma | August 2022 | August 2027 |
| NCT06335745 | Not yet recruiting | N/A | PediCARE Health Equity Intervention in High-Risk Neuroblastoma | September 2024 | April 1, 2030 |
| NCT06233903 | Not yet recruiting | Phase 2 | 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System | July 2024 | March 2025 |
| NCT06182410 | Not yet recruiting | Phase 2 | Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma | June 1, 2024 | March 31, 2027 |
| NCT06047535 | Not yet recruiting | Phase 4 | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. | October 31, 2023 | August 15, 2027 |
| NCT03583528 | Recruiting | DOTATOC PET/CT for Imaging NET Patients | July 11, 2018 | December 31, 2028 | |
| NCT04903899 | Recruiting | Phase 2 | 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma | May 19, 2021 | May 20, 2031 |
| NCT04936529 | Recruiting | Phase 2 | A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma | August 2, 2021 | June 15, 2025 |
| NCT04947501 | Recruiting | Early Phase 1 | A Study of N9 Chemotherapy in Children With Neuroblastoma | June 22, 2021 | June 22, 2025 |
| NCT01704716 | Recruiting | Phase 3 | High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) | February 2002 | September 2026 |
| NCT05027386 | Recruiting | Phase 2 | Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma | August 26, 2021 | December 30, 2025 |
| NCT05069220 | Recruiting | Early Phase 1 | 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor | September 1, 2021 | December 2026 |
| NCT00588068 | Recruiting | Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome | September 26, 2000 | September 2024 | |
| NCT05135975 | Recruiting | Phase 2 | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | October 18, 2021 | December 2029 |
| NCT05192980 | Recruiting | N/A | SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours | November 2, 2023 | November 2, 2038 |
| NCT05400603 | Recruiting | Phase 1 | Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma | November 6, 2023 | December 2025 |
| NCT05421897 | Recruiting | Phase 4 | Rapid Administration Pilot for Infusing Dinutuximab | October 24, 2022 | August 2024 |
| NCT05429502 | Recruiting | Phase 1/Phase 2 | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors | December 27, 2022 | January 29, 2029 |
| NCT05642455 | Recruiting | Phase 1/Phase 2 | SPEARHEAD-3 Pediatric Study | September 1, 2023 | July 30, 2038 |
| NCT02112617 | Recruiting | N/A | Phase II Study of Proton Radiation Therapy for Neuroblastoma | June 2014 | March 2028 |
| NCT05701306 | Recruiting | Phase 1 | APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors | February 28, 2023 | December 31, 2027 |
| NCT05755295 | Recruiting | N/A | Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma | April 3, 2023 | March 1, 2026 |
| NCT05770037 | Recruiting | Phase 2/Phase 3 | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers | December 18, 2023 | October 2029 |
| NCT05781919 | Recruiting | N/A | Use of Virtual Reality for Surgical Planning in Neuroblastoma | June 1, 2023 | October 31, 2025 |
| NCT05782959 | Recruiting | Phase 1 | Phase 1 Study of BCD-245 in Subjects With Neuroblastoma | November 29, 2021 | June 2023 |
| NCT05826158 | Recruiting | Phase 3 | 18F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastoma | June 6, 2022 | December 31, 2025 |
| NCT05890781 | Recruiting | N/A | Engineering Immune Organoids to Study Pediatric Cancer | May 12, 2023 | May 2028 |
| NCT02508038 | Recruiting | Phase 1 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | February 12, 2016 | December 2025 |
| NCT02558244 | Recruiting | Impact of Image-defined Risk Factors on the Outcome of Patients With Neuroblastoma: A Retrospective Study | January 2016 | October 2023 | |
| NCT02559778 | Recruiting | Phase 2 | Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | September 2015 | September 2035 |
| NCT02605421 | Recruiting | Phase 2 | Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma | June 2016 | July 2025 |
| NCT02679144 | Recruiting | Phase 2 | Neuroblastoma Maintenance Therapy Trial | February 2016 | February 2033 |
| NCT05990751 | Recruiting | Phase 1 | Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma | April 19, 2024 | December 2041 |
| NCT06000787 | Recruiting | N/A | MCT for the Harvard/UCSF ROBIN Center | September 19, 2023 | August 31, 2028 |
| NCT06013618 | Recruiting | Phase 2 | Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma | June 19, 2023 | December 31, 2024 |
| NCT02914405 | Recruiting | Phase 1 | Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma | May 24, 2018 | July 31, 2025 |
| NCT06057948 | Recruiting | Phase 2 | A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma | September 21, 2023 | March 21, 2026 |
| NCT06071897 | Recruiting | Phase 3 | Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma | September 1, 2023 | September 1, 2029 |
| NCT00107289 | Recruiting | Phase 2 | Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma | May 2006 | May 2025 |
| NCT06104488 | Recruiting | Phase 1 | A Study of Avutometinib for People With Solid Tumor Cancers | October 20, 2023 | October 20, 2029 |
| NCT00840047 | Recruiting | Phase 2 | Methionine PET/CT Studies In Patients With Cancer | July 20, 2009 | July 27, 2027 |
| NCT06172296 | Recruiting | Phase 3 | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | April 19, 2024 | December 31, 2029 |
| NCT03050268 | Recruiting | Familial Investigations of Childhood Cancer Predisposition | April 6, 2017 | March 31, 2037 | |
| NCT00898755 | Recruiting | Collecting and Storing Tissue From Young Patients With Cancer | March 5, 2007 | ||
| NCT03294954 | Recruiting | Phase 1 | GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma | January 18, 2018 | August 10, 2040 |
| NCT00695279 | Recruiting | Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products | January 4, 2007 | December 2036 | |
| NCT01005654 | Recruiting | Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms | October 7, 2009 | ||
| NCT03363373 | Recruiting | Phase 2 | Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow | April 3, 2018 | April 2028 |
| NCT03373097 | Recruiting | Phase 1/Phase 2 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | January 5, 2018 | December 2027 |
| NCT03382158 | Recruiting | International PPB/DICER1 Registry | December 6, 2016 | December 6, 2035 | |
| NCT01109394 | Recruiting | Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies | April 21, 2010 | ||
| NCT03496402 | Recruiting | N/A | Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) | April 20, 2018 | August 19, 2027 |
| NCT03503864 | Recruiting | Phase 2 | Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma | January 1, 2019 | December 30, 2028 |
| NCT06275334 | Recruiting | Dinutuximab Beta at the HUS and the Toulouse Oncopole | November 28, 2023 | November 28, 2024 | |
| NCT03541720 | Recruiting | Early Phase 1 | 18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma | April 30, 2019 | July 1, 2026 |
| NCT03561259 | Recruiting | Phase 2 | A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects | October 21, 2019 | April 2025 |
| NCT04897321 | Recruiting | Phase 1 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | July 6, 2022 | March 1, 2027 |
| NCT03618381 | Recruiting | Phase 1 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | June 18, 2019 | June 2040 |
| NCT06296732 | Recruiting | Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification | October 19, 2023 | November 1, 2031 | |
| NCT03721068 | Recruiting | Phase 1 | Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | February 19, 2019 | June 19, 2039 |
| NCT03966651 | Recruiting | Phase 1 | A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors. | April 17, 2023 | July 2025 |
| NCT04017104 | Recruiting | Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging | November 1, 2019 | August 1, 2024 | |
| NCT04023331 | Recruiting | Phase 1/Phase 2 | 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma | August 18, 2020 | December 2028 |
| NCT04040088 | Recruiting | Early Phase 1 | An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors | September 23, 2019 | July 2024 |
| NCT04239092 | Recruiting | Phase 1 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | June 5, 2020 | December 2024 |
| NCT04253015 | Recruiting | A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta | September 30, 2019 | June 15, 2032 | |
| NCT04301843 | Recruiting | Phase 2 | Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma | September 25, 2020 | October 1, 2033 |
| NCT04308330 | Recruiting | Phase 1 | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies | March 17, 2017 | December 31, 2024 |
| NCT04337177 | Recruiting | Phase 1 | Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | October 25, 2021 | June 2024 |
| NCT04559217 | Recruiting | Phase 2 | 68Ga-DOTATATE Neuroblastoma Imaging Pilot | December 6, 2021 | September 30, 2027 |
| NCT04706910 | Recruiting | Phase 3 | 18F-DOPA II - PET Imaging Optimization | January 20, 2021 | July 2026 |
| NCT01587300 | Recruiting | Neuroblastoma Biology Study | July 2011 | December 2099 | |
| NCT04837547 | Recruiting | Phase 1 | PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy | September 20, 2021 | September 2030 |
| NCT04851119 | Recruiting | Phase 1/Phase 2 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | November 8, 2021 | June 30, 2028 |
| NCT00602446 | Terminated | Phase 2 | Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant | August 2007 | December 2009 |
| NCT00788125 | Terminated | Phase 1/Phase 2 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | September 3, 2008 | July 30, 2022 |
| NCT00003513 | Terminated | Phase 2 | Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma | December 16, 1996 | March 29, 1999 |
| NCT01987596 | Terminated | Phase 3 | Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer | August 2013 | June 2018 |
| NCT00900068 | Terminated | Blood Samples From Patients on a Clinical Trial to CINV During HSCT | August 2008 | October 2009 | |
| NCT00428272 | Terminated | Phase 1 | HGS-ETR2 to Treat Children With Solid Tumors | December 4, 2006 | October 9, 2015 |
| NCT01077440 | Terminated | Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant | February 2010 | December 2014 | |
| NCT00533169 | Terminated | Phase 1 | ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma | September 2007 | February 2011 |
| NCT00089245 | Terminated | Phase 1 | Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer | February 5, 2004 | February 2, 2022 |
| NCT02693171 | Terminated | Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients | March 15, 2016 | December 19, 2016 | |
| NCT01404702 | Terminated | Phase 1 | Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma | August 2011 | August 2014 |
| NCT00698009 | Terminated | Phase 2 | Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma | June 2008 | June 2012 |
| NCT00324324 | Terminated | Phase 3 | Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant | May 2006 | December 2012 |
| NCT04730349 | Terminated | Phase 1/Phase 2 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer | June 3, 2021 | June 22, 2022 |
| NCT04753658 | Terminated | Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib | March 19, 2021 | September 30, 2022 | |
| NCT02536183 | Terminated | Phase 1 | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | October 2016 | October 2022 |
| NCT02163356 | Terminated | Phase 1 | Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma | May 2014 | May 2018 |
| NCT02164097 | Terminated | Phase 1 | ODSH + ICE Chemotherapy in Pediatric Solid Tumors | January 2015 | December 2017 |
| NCT03860207 | Terminated | Phase 1/Phase 2 | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | February 22, 2019 | October 20, 2021 |
| NCT01747876 | Terminated | Phase 1 | Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma | May 28, 2013 | June 29, 2017 |
| NCT02177773 | Terminated | Phase 1/Phase 2 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies | June 23, 2014 | August 7, 2017 |
| NCT03275402 | Terminated | Phase 2/Phase 3 | 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases | December 11, 2018 | June 2, 2023 |
| NCT01204450 | Terminated | Phase 1 | Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma | November 2009 | March 2013 |
| NCT00202930 | Terminated | Phase 2 | Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma | July 2005 | February 5, 2009 |
| NCT00582608 | Terminated | N/A | Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9 | October 2001 | May 2009 |
| NCT01183884 | Terminated | Phase 2 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma | August 2010 | November 9, 2018 |
| NCT02337309 | Terminated | Phase 1 | SF1126 for Patients With Relapsed or Refractory Neuroblastoma | July 9, 2015 | May 22, 2018 |
| NCT00946283 | Terminated | N/A | Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome | March 2010 | October 14, 2015 |
| NCT00670410 | Terminated | Phase 1 | Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma | November 2003 | December 2010 |
| NCT00539500 | Terminated | Phase 2/Phase 3 | Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma | October 2007 | September 5, 2012 |
| NCT01583842 | Terminated | Early Phase 1 | 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study | April 9, 2013 | February 25, 2021 |
| NCT00947167 | Terminated | Phase 2 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | March 2009 | May 2010 |
| NCT00960063 | Terminated | Phase 1 | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) | November 11, 2009 | December 22, 2010 |
| NCT00801931 | Terminated | Phase 1/Phase 2 | Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders | September 6, 2007 | May 5, 2009 |
| NCT02641782 | Terminated | Phase 2 | NB2013-HR German (GPOH) / Dutch (DCOG) Trial | November 2015 | January 30, 2017 |
| NCT00808899 | Terminated | Phase 2 | Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma | December 2008 | July 2009 |
| NCT02630043 | Terminated | Phase 1 | Trial of Tolcapone With Oxaliplatin for Neuroblastoma | December 2015 | July 2019 |
| NCT00813501 | Terminated | Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases | June 2008 | June 2010 | |
| NCT02624388 | Terminated | Phase 2 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) | August 2016 | September 2021 |
| NCT01505608 | Terminated | Phase 1/Phase 2 | Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma | December 2011 | December 2014 |
| NCT00651716 | Terminated | T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant | December 2006 | October 2019 | |
| NCT00003926 | Terminated | Phase 1 | Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | November 1998 | August 2003 |
| NCT03458728 | Terminated | Phase 1/Phase 2 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | April 30, 2018 | February 1, 2023 |
| NCT01483820 | Terminated | Phase 1/Phase 2 | Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma | December 2011 | December 2014 |
| NCT02780128 | Terminated | Phase 1 | Next Generation Personalized Neuroblastoma Therapy | July 2016 | August 2022 |
| NCT03545542 | Unknown status | N/A | Investigating the Microbiome and Volatile Organic Compound Profile of Children With Neuroblastoma | May 7, 2018 | December 31, 2022 |
| NCT02933333 | Unknown status | Phase 4 | G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor | September 27, 2016 | December 2020 |
| NCT00790413 | Unknown status | Early Phase 1 | Haploidentical Stem Cell Transplantation in Neuroblastoma | August 2005 | December 31, 2022 |
| NCT01295762 | Unknown status | N/A | Immunomonitoring of Children With Neuroblastoma | May 2011 | July 2019 |
| NCT01308905 | Unknown status | N/A | Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET) | February 2011 | February 2018 |
| NCT00798148 | Unknown status | Phase 1/Phase 2 | 131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma | September 2008 | |
| NCT00101309 | Unknown status | Phase 1 | Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma | November 2004 | |
| NCT04637503 | Unknown status | Phase 1/Phase 2 | 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma | November 18, 2020 | December 31, 2023 |
| NCT05179850 | Unknown status | Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Children | January 1, 2021 | December 31, 2023 | |
| NCT01701479 | Unknown status | Phase 1/Phase 2 | Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2) | January 2012 | December 2020 |
| NCT00939965 | Unknown status | N/A | Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma | February 2009 | |
| NCT00024193 | Unknown status | Phase 2 | Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Neuroblastoma | April 1999 | |
| NCT04864821 | Unknown status | Early Phase 1 | Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor | May 14, 2021 | May 14, 2023 |
| NCT00084695 | Unknown status | Phase 2 | Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases | September 2003 | |
| NCT01373736 | Unknown status | Phase 3 | 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors | ||
| NCT00013806 | Unknown status | Phase 2 | CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study | ||
| NCT01943097 | Unknown status | Evaluation of 18F-dopa and 123I-MIBG Uptake in the Patients With Neuroblastoma | June 2007 | December 2014 | |
| NCT00526318 | Unknown status | N/A | Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma | January 2007 | |
| NCT00003122 | Unknown status | Phase 2 | Surgery in Treating Patients With Neuroblastoma | December 1994 | |
| NCT01986595 | Unknown status | A Pilot Study on ALK Gene Mutations in Neuroblastoma | August 2013 | July 2014 | |
| NCT02013336 | Unknown status | Phase 1 | Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | December 2013 | December 2023 |
| NCT00417053 | Unknown status | Phase 3 | Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant | ||
| NCT00072488 | Unknown status | N/A | Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma | October 2004 | |
| NCT01525251 | Unknown status | Nurse Case Manager Model on Neuroblastoma Caregiver's Uncertainty | August 2009 | ||
| NCT01807468 | Unknown status | Phase 2 | Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors | May 2013 | June 2019 |
| NCT00416676 | Unknown status | Phase 3 | Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma | ||
| NCT00416559 | Unknown status | Phase 2 | Observation of Young Patients With Localized Neuroblastoma Who Have Undergone Surgery Only | December 2004 | |
| NCT00410631 | Unknown status | Phase 3 | Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma | October 2004 | |
| NCT00392340 | Unknown status | Phase 2 | Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma | March 2008 | |
| NCT00349024 | Unknown status | N/A | Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer | July 2005 | |
| NCT01156350 | Unknown status | Phase 2 | Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma | September 2011 | September 2014 |
| NCT02457650 | Unknown status | Phase 1 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | April 2015 | December 2019 |
| NCT00036712 | Unknown status | Phase 2 | Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation | January 2002 | |
| NCT00003743 | Unknown status | Phase 2 | Interleukin-2 in Treating Children With Stage IV Neuroblastoma Who Have Received Induction Therapy and Peripheral Stem Cell Transplantation | March 1997 | |
| NCT02615106 | Unknown status | Phase 2 | Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma | November 2015 | November 2018 |
| NCT00287950 | Unknown status | N/A | Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Infants With Neuroblastoma | September 1992 | |
| NCT02743429 | Unknown status | Phase 2 | Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma | March 27, 2015 | June 2024 |
| NCT00281905 | Unknown status | Phase 2 | Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors | June 1992 | |
| NCT00276731 | Unknown status | Phase 3 | Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma | March 1995 | |
| NCT00030719 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma | December 2001 | |
| NCT01916187 | Withdrawn | Phase 1 | Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma | July 30, 2013 | January 16, 2014 |
| NCT00874315 | Withdrawn | Phase 2 | Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL. | September 2008 | June 2012 |
| NCT01048086 | Withdrawn | Phase 2 | 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) | June 2009 | November 2013 |
| NCT00624962 | Withdrawn | N/A | Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors | March 2006 | January 2008 |
| NCT00992173 | Withdrawn | Phase 2 | Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma | January 2010 | |
| NCT01319838 | Withdrawn | Phase 1 | Aflac ST1001 Prolonged Isotretinoin | March 2011 | December 2013 |
| NCT00944580 | Withdrawn | Phase 1 | A Vaccine Study for High Risk Cancers | June 2009 | August 2010 |
| NCT03209869 | Withdrawn | Phase 1 | Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2 | March 12, 2018 | September 7, 2022 |
| NCT02439788 | Withdrawn | Phase 1 | 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA | August 2017 | October 2030 |
| NCT00389766 | Withdrawn | Phase 2 | High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma | July 2008 | |
| NCT03013387 | Withdrawn | Phase 2 | Dosimetry Guided PRRT With 90Y-DOTATOC | January 2017 | October 2019 |
| NCT02745756 | Withdrawn | Phase 1 | A Combined Cell Therapy Approach to the Treatment of Neuroblastoma | April 14, 2016 | August 21, 2017 |
| NCT01130623 | Withdrawn | Phase 1 | A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors | May 10, 2010 | November 18, 2011 |
| NCT02557854 | Withdrawn | Phase 1 | HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors | December 2016 | March 16, 2019 |
| NCT01174537 | Withdrawn | Phase 1/Phase 2 | New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma | July 2011 | July 2011 |
| NCT04909515 | Withdrawn | Phase 2 | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. | December 2, 2021 | April 2027 |
| NCT00003273 | Withdrawn | Phase 2 | Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor | November 1997 |
- Disase is a (Disease Ontology)
- DOID:2621
- Cross Reference ID (Disease Ontology)
- EFO:0000621
- Cross Reference ID (Disease Ontology)
- GARD:7185
- Cross Reference ID (Disease Ontology)
- ICDO:9500/3
- Cross Reference ID (Disease Ontology)
- MESH:D009447
- Cross Reference ID (Disease Ontology)
- NCI:C3270
- Cross Reference ID (Disease Ontology)
- ORDO:635
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:432328008
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0027819
- HPO alt_id (Human Phenotype Ontology)
- HP:0006738
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0003006
- OrphaNumber from OrphaNet (Orphanet)
- 635
- MedGen concept unique identifier (MedGen Concept name)
- CN205405
- MedGen unique identifier (MedGen Concept name)
- 798120
- MeSH unique ID (MeSH (Medical Subject Headings))
- D009447